EGFR (Endothelial growth factor receptor) is a well-known target for anticancer therapies, especially for non-small lung cancer (NSCLC) treatment, but the T790M mutation in the EGFR ATP site has recently caused a lack of EGFR-targeted therapy. Here, EGFR is linked to non-small cell lung carcinoma.